Gain Therapeutics, Inc.

What they do

Gain Therapeutics uses its computational platform, Magellan, to discover allosteric binding sites on proteins and identify proprietary small molecules that modulate protein function. The company's pipeline focuses on CNS disorders, lysosomal storage disorders, metabolic disorders, and oncology. Its lead product candidate, rexaceract (GT-02287), is being developed for Parkinson's disease with or without GBA1 mutations, and has completed Phase 1a and Phase 1b Part 1 studies. A second candidate, GT-04686, is moving towards IND-enabling studies.

Revenue drivers

• Collaboration and licensing revenue — Revenue has been minimal, derived from collaboration or licensing arrangements; annual revenue ranged from $28,881 in 2020 to $133,928 in 2021, with $55,180 in 2023.

Recent performance

As of June 30, 2026, the company had $13.1 million in cash and equivalents, total assets of $15.4 million, and shareholder equity of $11.3 million. Net loss for 2025 was $20.2 million, with operating cash flow of -$18.5 million. Diluted EPS for 2025 was -$0.61. In Q2 2026, the company reported FDA authorization of its IND for rexaceract, paving the way for Phase 2 initiation. The Phase 1b extension is ongoing, with 14 of 16 participants completing Day 270 and seven reaching Day 360 as of June 30, 2026.

Strategy

Gain Therapeutics plans to advance rexaceract into Phase 2 clinical development in the U.S., expected to commence in the second half of 2026. The company will continue to present data from the Phase 1b extension, including final data at the International Congress of Parkinson's Disease and Movement Disorders in October 2026. The company is also advancing GT-04686, its second allosteric modulator from the Magellan platform, towards IND-enabling studies, with an initial therapeutic indication expected by year end. Management emphasizes the potential of rexaceract to shift the treatment paradigm beyond symptom management by addressing the underlying biology of Parkinson's disease.

Risks

• Going concern risk — There is substantial doubt about the company's ability to continue as a going concern due to a history of operating losses and expected future losses.
• Financing risk — The company will need to raise additional capital, and such financing may not be available on acceptable terms or at all.
• Clinical development risk — Rexaceract is still in Phase 1b/Phase 2; failure to demonstrate safety and efficacy in larger trials could halt development.
• Competition and market risk — The Parkinson's disease treatment landscape is competitive, and other therapies may emerge that could limit commercial potential.

Outlook

Management expects to complete Part 2 of the Phase 1b study in September 2026 and to initiate a Phase 2 study during the second half of 2026. Final Phase 1b data are expected to be presented in October 2026. The company continues to monitor macroeconomic conditions, including geopolitical tensions and supply chain disruptions, which could impact operations and financing access.